1. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/humira. Accessed 17 Feb 2022.
2. Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, et al. Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34:e470–2.
3. Barker J, Girolomoni G, Egeberg A, Goncalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat. 2020;31:794–800.
4. The European Medicines Agency, The European Commission. Biosimilars in the EU - Information guide for healthcare professionals. In: Prepared jointly by the European Medicines Agency and the European Commission. ©European Med Agency. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 1 Feb 2022.
5. Prignano F, Choi J, Pieper B, Iversen L. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opin Biol Ther. 2021;21:75–80.